Navigation Links
Sinovac Named One of China's Top 10 Most Competitive Companies Listed Overseas in 2009

BEIJING, Dec. 21 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009. The honor was given to Sinovac at the 2009 China Business Annual Meeting on Enterprise Competitiveness.

The "Competitiveness Measure" is the measuring model developed by the experts from the Research Center of Chinese Industries and Enterprise Competitiveness and China Business Media. The model evaluates the competitiveness of Chinese listed companies through the criteria including the listed companies' sales revenue, net assets, net profits, the sales revenue, growth rate of net profits, and return on net assets in the past three years. The evaluation result will become an objective and authoritative reference for management and investors.

Sinovac, an independent company publicly traded on the NASDAQ Global Market, shares a position on the list with some of China's large "State-owned Enterprises" such as China National Offshore Oil, PetroChina, China Mobile (Hong Kong), China Unicom, and China Petroleum & Chemical. Completing the Top 10 list are Yingli Green Energy Holdings Co., Ltd., Gushan Environmental Energy Limited, LDK Solar Co., Ltd., and Changzhou Trina Solar Energy Co., Ltd.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We would like to thank China Business and the Institute of Industrial Economics of the Chinese Academy of Social Sciences for bestowing this designation on our Company as it recognizes our collective and successful efforts to develop and commercialize vaccines within a competitive marketplace."

The Annual Meeting on Enterprise Competitiveness has been held since 2003 and is China's only economic forum combining theoretical research and economic practice. The key contents of the annual meeting include: issuing the research results of the Institute of Industrial Economics of the Chinese Academy of Social Sciences and China Business Media; releasing survey results on the competitiveness of listed Chinese enterprises based on analysis of annual report data; and inviting well-known entrepreneurs, economists, and governmental officials to discuss the hottest economic issues for the current year.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and PANFLU.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910

     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017

     Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7033

SOURCE Sinovac Biotech Ltd.

SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
4. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
5. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
6. Sinovac Files Shelf Registration Statement
7. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
8. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
9. Aspirin Named 8th World Wonder by Majority of Americans
10. American Board of Internal Medicine President Named to Alzheimers Study Group
11. New York Infection Prevention Expert Named Recipient of Carole DeMille Award
Post Your Comments:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):